Jump to main content
Takeda will discontinue global manufacturing of NATPARA by the end of 2024. Learn How This May Affect You

Understanding Hypoparathyroidism

Hypoparathyroidism interferes with calcium homeostasis2

Hypoparathyroidism is a complex endocrine disorder characterized by absent or inappropriately low levels of parathyroid hormone (PTH). Compromised endogenous PTH function can lead to hypocalcemia.2-4

Calcium levels can be maintained through interactions that involve endogenous PTH and the bones, kidneys, intestines, and the active form of vitamin D2

Graph of normal PTH function.

Insufficient endogenous PTH can interfere with certain processes of these organs which can lead to2,3:

  • Decreased intestinal calcium absorption due to a decrease in the conversion of vitamin D to its active form
  • Decreased renal reabsorption of calcium
  • Decreased bone turnover
Graph of compromised PTH function.

References: 1. NATPARA [package insert]. Shire Pharmaceuticals, Inc. 2. Shoback D. N Engl J Med. 2008;359(4):391-403. 3. Bilezikian JP, Khan A, Potts JT Jr, et al. J Bone Miner Res. 2011;26(10):2317-2337. 4. Fong J, Khan A. Can Fam Physician. 2012;58(2):158-162.

NATPARA® and the NATPARA Logo® are registered trademarks of Takeda Pharmaceuticals, U.S.A,. Inc.